Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.62 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.62 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.62 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.62 |
| ▸ | HTR3B | O95264 | 1/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.62 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.62 |
| ▸ | HTR3A | P46098 | 1/20 | 0.62 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.62 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.62 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.62 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671121 | 0.88 | CYP3A4 (0.52) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL9675763 | 0.86 | CYP3A4 (0.51) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Hydrochloric Acid SCHEMBL7411277 | 0.85 | CYP3A4 (0.48) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL10663966 | 0.84 | CYP3A4 (0.49) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Bromide SCHEMBL10663174 | 0.84 | CYP3A4 (0.49) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL19118074 | 0.83 | CYP3A4 (0.42) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL10663181 | 0.83 | CYP3A4 (0.48) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Oxalic Acid SCHEMBL10659402 | 0.83 | CYP3A4 (0.48) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| SCHEMBL10659409 | 0.82 | CYP3A4 (0.47) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E | |
| Maleic Acid SCHEMBL10664048 | 0.81 | CYP3A4 (0.47) | CYP3A4KCNH2CYP1A2CYP2D6HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239866-B2 | Selective methods for the separation of ondansetron and related impurities | WATERS TECHNOLOGIES CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170197942-A1 | SELECTIVE METHODS FOR THE SEPARATION OF ONDANSETRON AND RELATED IMPURITIES | WATERS TECHNOLOGIES CORPORATION | 2017-07-13 | — | — | US | disclosed |
| US-20170197942-A1 | SELECTIVE METHODS FOR THE SEPARATION OF ONDANSETRON AND RELATED IMPURITIES | WATERS TECHNOLOGIES CORPORATION | 2017-07-13 | — | — | US | disclosed |
| WO-2013106460-A2 | COMPOSITIONS AND METHODS FOR TREATING MALIGNANT ASTROCYTOMAS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-07-18 | — | — | WO | disclosed |
| US-7547791-B2 | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | IPCA LABORATORIES LTD. (IN) | 2009-06-16 | — | — | US | disclosed |
| US-7547791-B2 | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | IPCA LABORATORIES LTD. (IN) | 2009-06-16 | — | — | US | disclosed |
| US-7547791-B2 | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O | IPCA LABORATORIES LTD. (IN) | 2009-06-16 | — | — | US | disclosed |
| US-7521565-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one or its salt | YUHAN CORPORATION (KR) | 2009-04-21 | — | — | US | disclosed |
| US-7521565-B2 | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazole-1-yl)methyl]-4H-carbazol-4-one or its salt | YUHAN CORPORATION (KR) | 2009-04-21 | — | — | US | disclosed |
| EP-1828141-A4 | A ONE-POT PROCESS FOR THE PREPARATION OF ANTIEMETIC AGENT, 1,2,3,9-TETRAHYDRO-9-METHYL-3[(2-METHYL)-1H-IMIDAZOLE-1-YL)METHYL]-4H-CARBAZOL-4-O | IPCA LAB LTD (IN) | 2009-04-01 | — | — | EP | disclosed |
| EP-1499623-A1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE | BIOGAL GYOGYSZERGYAR RT. (HU) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003093281-A1 | PROCESS FOR PREPARING 1,2,3,9-TETRAHYDRO-9-METHYL-3-[(2-METHYL-1H-IMIDAZOL-1-YL)METHYL]-4H-CARBAZOL-4-ONE | BIOGAL GYOGYSZERGYAR RT. (HU) | 2003-11-13 | — | — | WO | disclosed |
| EP-0210840-B1 | SUBSTITUTED IMIDAZOLYLMETHYLTETRAHYDRO-CARBAZOLONES | GLAXO GROUP LIMITED (GB) | 1992-03-11 | — | — | EP | disclosed |
| EP-0191562-B1 | TETRAHYDROCARBAZOLONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1991-07-10 | — | — | EP | disclosed |
| US-4957609-A | CYCLIZATION | GLAXO GROUP LIMITED (GB) | 1990-09-18 | — | — | US | disclosed |
| US-4749718-A | NEUROLEPTIC AND GASTROINTESTINAL AGENTS | GLAXO GROUP LIMITED (GB) | 1988-06-07 | — | — | US | disclosed |
| US-4695578-A | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances | GLAXO GROUP LIMITED (GB) | 1987-09-22 | — | — | US | disclosed |
| EP-0221629-A1 | Process for the preparation of 3-imidazolylmethyltetrahydrocarbazolones | GLAXO GROUP LIMITED (GB) | 1987-05-13 | — | — | EP | disclosed |
| EP-0210840-A2 | Substituted imidazolylmethyltetrahydro-carbazolones | GLAXO GROUP LIMITED (GB) | 1987-02-04 | — | — | EP | disclosed |
| EP-0191562-A2 | Tetrahydrocarbazolone derivatives | GLAXO GROUP LIMITED (GB) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197942-A1 | SELECTIVE METHODS FOR THE SEPARATION OF ONDANSETRON AND RELATED IMPURITIES | HTR2C, HTR4, HTR2B | CYP3A4 23/4885KCNH2 478/4885CYP1A2 143/4885 |
| US-10239866-B2 | Selective methods for the separation of ondansetron and related impurities | HTR2C, HTR4, HTR2B | CYP3A4 23/4885KCNH2 478/4885CYP1A2 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.